Predictable outcomes, correlatable to pre-, peri- and post-Tx evidence.
Regenerative and personalized medicine is based on the body's innate reparative, immunomodulatory and regenerative capabilities. There is an enormous, definitive and growing body of peer-reviewed scientific literature dedicated to these areas. Obtaining predictable outcomes for specific indications and patient cohorts requires, first and foremost, an understanding of that science. It also requires, however, the design of processes for its efficient application in the context of a busy clinical practice. Our Clinical/Scientific Advisory Board and global network comprise recognized leaders in cell science, and the practical clinical translation of that science.
From basic endotoxin screens to flow cytometry, we procure devices and design models for clinically accessible characterization methods.
READ MORE
inCytes™ allows clinicians to design, capture, report and share unique clinical evidence.
READ MORE
We assemble external, multi-disciplinary advisory committees to establish strong foundations for scientific excellence, medical ethics and international growth.
READ MORE
We connect our partners with the thriving Regenerative Medicine device industry to help support pre and post-market studies and trials.
READ MOREBoard Member
Regen Med
Diego Correa has over 15 years of basic and translational research experience in the areas of Adult Stem Cell Biology and Regenerative Medicine, emphasizing on musculoskeletal tissue development, injury and repair, tissue engineering, stem cell-based therapies and oncology (adult stem cells in primary and metastatic tumor formation).
READ MOREBoard Member
Regen Med
Dr. Alan Russell (Ph.D. in Biological Chemistry, 1987, Imperial College of Science and Technology, University of London) is the Highmark Distinguished Career Professor at Carnegie Mellon University and Director of CMU’s Disruptive Health Technology Institute.
READ MOREBoard Member
Regen Med
Christian is head of the clinical unit, “Immuno-therapy Rheumatology”, at the University Hospital “Lapeyronie” (Montpellier). He leads Institute IRMB dedicated to regenerative medicine, and the clinical department for immunotherapy with 20 beds dedicated to biotherapy applied to Rheumatoid Arthritis and other autoimmune diseases.
READ MORE